T ype 2 diabetes mellitus is a powerful cardiovascular disease (CVD) risk factor. 1, 2 This may in part be because of the presence of the atherogenic dylipidemia characterized by elevated plasma triglyceride and low high-density lipoprotein (HDL) cholesterol concentrations. 3 Statin therapy is the frontline treatment for dyslipidemia in type 2 diabetes mellitus. 3 Statins effectively lower low-density lipoprotein (LDL) cholesterol with modest triglyceride-lowering and HDL cholesterol-raising effects. Statins generally do not lower plasma concentrations of lipoprotein(a) (Lp(a)), an emerging CVD risk factor in the general population, 4,5 and type 2 diabetes mellitus. 6, 7 Nicotinic acid or niacin is an essential B-complex vitamin. At pharmacological doses, niacin has moderate LDL cholesterol-lowering effects, however. 8, 9 Niacin, nonetheless, effectively lowers plasma triglycerides and raises HDL cholesterol concentrations. 8, 9 Niacin is also one of few agents that can significantly lower plasma Lp(a) concentrations. 8-10 Niacin is not widely used, however, owing to poor tolerability. The newer extended release formulation is better tolerated, however.
including the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treament of HDL to Reduce the Incidence of Vascular Events (HPS-2 THRIVE), where niacin is added to aggressive LDL cholesterol-lowering statin therapy failed to demonstrate benefits. 12, 13 However, the cardiovascular benefits of niacin may be restricted to patients with elevated plasma triglyceride and HDL cholesterol. 14 In addition, there is compelling data to support the use of niacin in combination with statins to treat the atherogenic dyslipidemia. [8] [9] [10] Studies to better understand the mechanism of action of niacin, therefore, are merited.
Few studies have examined the effect of niacin on lipoprotein metabolism. That the findings have been inconclusive may be, in part, related to small sample size and varying participant characteristics. [15] [16] [17] Furthermore, no studies have examined the effect of niacin in combination with optimal statin therapy, in the postprandial state, or in type 2 diabetes mellitus. This study, therefore, aimed to investigate the effect of niacin on lipoprotein metabolism, with a focus on Lp(a), in men with type 2 diabetes mellitus on background optimal statin therapy. We also examined the effect of niacin on the metabolism of apolipoprotein (apo) B-100-containing lipoproteins. The effect of niacin on HDL metabolism in these individuals were reported previously. 18 We hypothesized that niacin would decrease Lp(a) concentrations by decreasing the production rates (PR) of apo(a) and Lp(a)-apoB-100 in men with type 2 diabetes mellitus. We also hypothesized that niacin would decrease the concentrations of apoB-100-containing lipoproteins by decreasing the PR of these particles.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Table 1 shows the clinical and biochemical characteristics of the 11 men with type 2 diabetes mellitus at randomization. These individuals had well-controlled plasma LDL cholesterol, low HDL cholesterol, and moderately elevated triglyceride concentrations. All participants took 100 mg of aspirin daily for the duration of the trial to minimize flushing. Table 2 shows the plasma lipid, lipoprotein, apolipoprotein, glucose, and insulin concentrations at the end of each intervention period. Compared with rosuvastatin, the combination of rosuvastatin+extended-release niacin (ERN) significantly decreased plasma total, LDL, and non-HDL cholesterol, apoB-100, and triglyceride and increased HDL cholesterol and apoA-I concentrations. There was a significant increase in plasma glucose with rosuvastatin+ERN, but insulin and the homeostatic model assessment score was not altered significantly. Plasma proprotein convertase subtilisin-like/kexin type 9 (PCSK9) concentration decreased with rosuvastatin+ERN, but this failed to reach statistical significance (P=0.06). Carry-over effects were tested and not found significant for the above mentioned parameters. Tracer metabolic studies were performed in the nonsteady state. Participants consumed a liquid formulation high-fat test meal (oral fat load; 87% fat), resulting in postprandial changes in plasma triglycerides ( Figure I in the online-only Data Supplement), but not plasma Lp(a). Figure 1 shows the fit of the model to the tracer-to-tracee ratio for Lp(a) protein components, apo(a) and Lp(a)-apoB-100, in a representative participant at the end of each intervention period. The corresponding apo(a) and Lp(a)-apoB-100 fractional catabolic rates (FCR) are 0.88 and 1.09, and 1.20 and 1.87 pools/d for rosuvastatin and rosuvastatin+ERN, respectively. Figure 2 shows the fit of the model to the very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL apoB-100 tracer data after administration of D 3 -leucine and to the VLDL apoB-100 concentrations in response to the oral fat load in a representative participant at the end of each intervention period. The corresponding VLDL, IDL, and LDL apoB-100 FCR are 5.28, 2.33 and 0.38, and 8.38, 1.28 and 0.25 pools/d for rosuvastatin and rosuvastatin+ERN, respectively. Plasma leucine tracer curves did not differ significantly between interventions. Details of the multicompartmental models for Lp(a) and apoB-100-containing lipoproteins are provided in the online-only Data Supplement. Table 3 shows the concentrations and kinetic parameters for Lp(a) protein components, apo(a) and Lp(a)-apoB-100, as well as VLDL, IDL, and LDL apoB-100 after interventions with rosuvastatin and rosuvastatin+ERN. Compared with rosuvastatin alone, rosuvastatin+ERN significantly decreased plasma Lp(a) concentration and the PR of apo(a) and Lp(a)-apoB-100. No significant changes to apo(a) or Lp(a)-apoB-100 FCR were observed. The basal (synonymous with the fasted state) concentrations and PR of VLDL, IDL, and LDL apoB-100 were significantly decreased with rosuvastatin+ERN compared with rosuvastatin alone. Basal IDL and LDL, but not VLDL, apoB-100 FCR were also significantly decreased with rosuvastatin+ERN. The number of VLDL apoB-100 particles secreted into plasma on top of basal VLDL apoB-100 secretion increased in response to the oral fat load. The increase was greater with rosuvastatin+ERN Figure II in the online-only Data Supplement). Despite this, total (basal+postoral fat load) VLDL apoB-100 production over the 10-hour postprandial period was significantly decreased with rosuvastatin+ERN compared with rosuvastatin alone (Table 3 ; Figure II in the online-only Data Supplement). The total area under the curve over the 10-hour postprandial period was decreased with rosuvastatin+ERN (689±107 versus 450±57.9, mg/L h; P=0.03). No significant changes in the direct secretion of IDL (mean±SEM: 0.69±0.37 versus 0.58±0.24, mg/ kg/d; P=0.75) or LDL (0.53±0.14 versus 0.42±0.13, mg/ kg/d; P=0.42) were observed with rosuvastatin+ERN compared with rosuvastatin alone. The transport of VLDL to IDL (7.97±0.88 versus 4.64±0.71, mg/kg/d; P<0.01) and IDL to LDL (8.59±0.88 versus 4.95±0.60, mg/kg/d; P<0.01) were significantly decreased with rosuvastatin+ERN. The aforementioned kinetic parameters remained significantly different between rosuvastatin+ERN compared with rosuvastatin alone after adjustment for fasting glucose concentration. Table 4 shows Lp(a) concentrations and the kinetic parameters of its protein components in individual participants, grouped according to low and high plasma Lp(a) concentrations, with low defined as below and high as above the median (42nmol/L) plasma Lp(a) concentration. In between-group analyses, the high Lp(a) group had significantly lower number of Kringle IV domains. This group also had higher plasma Lp(a) concentration and apo(a) and Lp(a)-apoB-100 PR (all P<0.01). The FCR of Lp(a)-apoB-100 was significantly slower in the high Lp(a) group, but apo(a) FCR was not different between groups. Within the low Lp(a) group, apo(a) FCR and PR were significantly lower compared with those of Lp(a)-apoB-100. By contrast, within the high Lp(a) group, apo(a) FCR and PR were significantly higher than those of Lp(a)-apoB-100. Changes in Lp(a) concentration (low versus high: −9.5% versus −28%) and apo(a) (−3.5% versus −37.2%) and Lp(a)-apoB-100 (−6.4% versus −30.6%) PR were significantly greater (all P group effect <0.05; Figure III in the online-only Data Supplement) with rosuvastatin+ERN in the high Lp(a) group.
Results

Discussion
We report on the effects of ERN, added to the background of statin therapy, on Lp(a) metabolism and apoB-100-containing lipoproteins in men with type 2 diabetes mellitus. We showed On lipid-lowering medication (n) 11
On antidiabetic medication (n) 10
On antihypertensive medication (n) 8
To convert total, LDL, and HDL cholesterol in mmol/L to mg/dL, divide by 0.0259; triglycerides in mmol/L to mg/dL, divide by 0.0113. HDL indicates highdensity lipoprotein; HOMA, homeostatic model assessment; LDL, low-density lipoprotein; and SD, standard deviation. that ERN significantly decreased plasma Lp(a) concentration and the PR of apo(a) and Lp(a)-apoB-100; the effect being greater in individuals with higher Lp(a) concentrations. These changes were achieved without alterations to body weight, blood pressure, or dietary intake and independent of changes in plasma glucose concentration. In addition, ERN significantly decreased the concentrations of apoB-100-containing lipoproteins by decreasing the transport of these particles down the VLDL to LDL cascade. The number of VLDL apoB-100 particles secreted increased in response to the fat load. Despite this, total VLDL apoB-100 production over the 10-hour postprandial period was significantly decreased with ERN. The plasma triglyceride and LDL cholesterol-lowering and HDL cholesterol-raising effects are consistent with previous reports. 8, 9 Previous kinetic studies using radioisotope and stable isotope methods have examined the effect of niacin on apoBcontaining lipoproteins in the steady state. Kushwaha fatty liver disease. 15 In 5 men with combine hyperlipidemia, Lamon-Fava et al reported that ERN (2 g/d for 12 weeks) decreased VLDL apoB-100 concentration by increasing its FCR, with no changes to IDL and LDL concentrations or kinetics. 16 Discrepancies among studies may relate to differences in participant clinical characteristics, in study design and sample size, and in dose and duration of intervention.
To date, only one study has examined the effect of niacin on the metabolism of Lp(a). In 8 nondiabetic, obese men with hypertriglyceridemia, Croyal et al reported that ERN (2 g/d for 8 weeks) decreased plasma apo(a) concentration, PR, and FCR measured using stable isotope, liquid chromatographytandem mass spectrometry method, and monocompartmental modeling in the fasted state. 19 No studies have examined the effects of niacin on the metabolism of Lp(a) and its protein components, apo(a) and Lp(a)-apoB-100, or that of apoB-100-containing lipoproteins after an oral fat load. We, therefore, extend previous reports by examining the effect of ERN on the metabolism of Lp(a) and its protein components in men with type 2 diabetes mellitus on background optimal statin therapy using a randomized, crossover study design. This study also examined, in the same individuals, the effect of ERN on the metabolism of apoB-100-containing lipoproteins in the nonsteady state. Studies in transgenic mice have shown reductions in apo(a) concentration and APOA mRNA expression with niacin intervention. 20 Niacin has also been shown to downregulate human APOA promoter activity and, hence, APOA transcription in HepG2 cells. 20 Our finding that ERN decreased apo(a) PR is consistent with this notion. The previously reported effects of niacin on hepatic triglyceride synthesis may explain the reductions in Lp(a)-apoB-100 PR with ERN. In particular, niacin inhibits the activity of diacylglycerol acyltransferase-2, the rate-limiting enzyme that catalyzes the final reaction in Table 3 triglyceride synthesis, 21 and upregulates intrahepatic fatty acid oxidation 15 and, hence, its availability for triglyceride synthesis. This results in a reduction in the lipid pool that protects apoB-100 from post-translational degradation 22 and, hence, apoB-100 secretion and the pool of apoB available to bind with apo(a). Of interest, the effects of ERN on Lp(a) concentration and apo(a) and Lp(a)-apoB-100 kinetics were greater in individuals with the smaller apo(a) isoform size (elevated Lp(a) concentration), consistent with recent reports. 23 Whether niacin could confer cardiovascular benefits via Lp(a) reductions in these individuals is unclear, however. The plasma Lp(a) reduction of 19% with ERN in the AIM-HIGH study was not associated with reduction in CVD events, 10 even though recent subanalyses suggest potential cardiovascular benefits of ERN in individuals with mixed dyslipidemia. 14 It is also possible that niacin may confer CVD benefits in those who sustain acute coronary syndrome and myocardial infarction given its favorable effect on atherosclerotic plaque structure. 24 Whether lowering Lp(a) specifically confers CVD benefits can only be addressed by therapeutic interventions that selectively lower Lp(a). 10 Recent in vitro studies point to a role of the LDL receptor in the catabolism of Lp(a). 25 These data, however, suggest that the catabolism of Lp(a) is primarily mediated via apoB-100 rather than apo(a) and chiefly at supraphysiological LDL receptor levels. 25 In contrast, studies in homozygous and heterozygous familial hypercholesterolemia patients with little or no LDL receptor activity showed that the absence of a functional LDL receptor was not associated with delayed Lp(a) catabolism. 26 Although ERN decreased plasma PCSK9 concentration in our study and potentially increased LDL receptor recycling, this was not associated with any significant changes in apo(a) or Lp(a)-apoB-100 catabolism. Our finding differs to that reported by Croyal et al showing reductions in apo(a) FCR with ERN. 19 The authors concluded that the LDL receptor and PCSK9 did not play a central role in apo(a) catabolism, but conceded that this may be a consequence of not examining the kinetics of Lp(a)-apoB-100. It is noteworthy that these participants did not have type 2 diabetes mellitus, were hypertriglyceridemic, and were not on statin treatment. By contrast, our participants were on optimal background statin treatment, and it is possible that the magnitude of PCSK9 reduction and, by implication, increase in LDL receptor activity was insufficient to alter Lp(a) catabolism. Future studies on the effect of PCSK9 inhibitors on Lp(a) metabolism are warranted.
. Kinetic Estimates of the Metabolism of apoB-100-Containing Lipoproteins and Lp(a) After Treatment With Rosuvastatin and Rosuvastatin+Extended-Release Niacin
That apo(a) secretion is higher in individuals with elevated Lp(a) supports the notion that apo(a) secretion and isoform size are key determinants of Lp(a) concentration. 27, 28 In parallel, the higher Lp(a)-apoB-100 secretion supports the notion that apoB-100 is a major determinant of Lp(a) concentrations. 29 Moreover, it may provide a mechanism by which therapies targeting apoB-100 synthesis and secretion could lower Lp(a) concentrations, 30, 31 although this remains to be investigated. The uncoupling of apo(a) and Lp(a)-apoB-100 metabolism is consistent with the notion that apo(a) and apoB-100 may associate and dissociate in plasma. 32 It is also consistent with the concept that Lp(a) may be assembled intracellularly and extracellularly. [32] [33] [34] [35] [36] We demonstrated that ERN decreased VLDL, IDL, and LDL apoB-100 PR in the basal state. The reductions in VLDL apoB-100 PR are consistent with the notion that niacin decreases hepatic apoB secretion. 22 The reductions in IDL and LDL apoB-100 PR may relate to reductions in transport of these particles down the VLDL to LDL cascade or to decreases in the direct hepatic secretion of these particles. Our results were more consistent with the former mechanism and are likely attributable to markedly reduced VLDL apoB-100 secretion. We also showed concurrent reductions in IDL and LDL apoB-100 FCR with ERN. The fall in PCSK9 concentration with ERN might translate to increased LDL receptor activity 37 and, thus, increased LDL catabolism. However, that IDL and LDL FCR fell with ERN suggests that changes to IDL and LDL concentration are primarily because of decreased apoB hepatic secretion and transport. We found that the number of VLDL apoB-100 particles secreted into plasma increased in response to the oral fat load, the increase being marginally higher with ERN. Whether this relates to altered suppression of fatty acid spillover, a consequence of lipoprotein lipase hydrolysis of meal triglyceride, a potential contributor for fatty acid pool and substrate for hepatic triglyceride synthesis, 38, 39 is unclear. Despite this, total VLDL apoB-100 production over the 10-hour postprandial period was significantly decreased with ERN.
Our study found that fasting plasma glucose concentrations increased with ERN, consistent with earlier reports. 8, 9 Plasma glucose concentration did not change significantly in response to the oral fat load (data not shown) with ERN, however. It is noteworthy that the lipid-regulating effects of ERN were independent of the changes in glucose concentrations.
Our study has limitations. First, we studied only white men. Although this largely eliminates population admixture as a potential confounder, future studies in women and populations of different ethnicity and disease states are warranted. Second, our study focused on the metabolic fate of the predominant apo(a) isoform and in whole plasma. Future studies to examine the effect of ERN on the concentrations and kinetics of the secondary apo(a) isoform are warranted. Future studies that selectively recruit individuals with low and elevated (>95th percentile) plasma Lp(a) concentrations are also warranted. Third, although plasma Lp(a) concentrations remained constant after the oral fat load, we cannot exclude that the distribution of apo(a) between lipoprotein fractions may be altered. Studies on the metabolism of apo(a) within the triglyceride-rich lipoprotein fraction, after an oral fat load, are also of interest. Fourth, the kinetics of VLDL subspecies and triglycerides were not examined, but we anticipate that their production will also be decreased with ERN. Fifth, although we separated apoB-100 from apoB-48 within the d<1.006 g/mL fraction, we cannot exclude a small degree of contamination by apoB-48-containing particles. In addition, the triglyceride-lowering effect of ERN might be in part because of reductions in apoB-48-containing particles. The effects of ERN on the metabolism of these particles merit investigation. Finally, apoB-100-containing lipoprotein particles may exhibit kinetic and structural heterogeneity based on the complement of regulatory apolipoproteins. Studies to examine the effect of ERN on the concentration and kinetics of these apolipoproteins may further corroborate our findings.
In conclusion, in statin-treated men with type 2 diabetes mellitus, ERN decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100. ERN also decreased the concentrations of apoB-100-containing lipoproteins by decreasing VLDL production and the transport of these particles down the VLDL to LDL cascade. Our study provides further mechanistic insights into the lipidregulating effects of ERN.
